Exparel, a product of Pacira Pharmaceuticals (PCRX), is one of the leading non-opioid analgesics in pain management. Pacira is a rising specialty pharmaceutical company focused on hospital-based products for pain management. It is well known for its DepoFoam Technology, an injectable drug delivery technology that allows both immediate and sustained release of therapies. Its established product DepoCyt is used for treating cancer-related lymphomatous meningitis.
I believe that the company has tremendous growth potential due to its anesthetic product Exparel, which is currently approved only for use via surgical wound infiltration. The positive results from the first part of its Phase II/III study testing Exparel as a single-dose injection through femoral nerve block in patients undergoing total...
Only subscribers can access this article, which is part of the PRO research library covering 3,572 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: